Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px
Person › Details

Mehdi Shahidi (Boehringer Ingelheim (Group))

Shahidi, Mehdi (Boehringer 201903– CMO before Global Head Oncology joined in 2005)


Organisation Organisation Boehringer Ingelheim (Group)
Products Product pharmaceutical
  Product 2 clinical research

Boehringer Ingelheim. (2/25/19). "Press Release: New Chief Medical Officer Appointed". Ingelheim.

Boehringer Ingelheim today announced that Dr Mehdi Shahidi, currently Global Head of Medicine in the Therapeutic Area Oncology of Boehringer Ingelheim will take over the role of Corporate Senior Vice President Medicine and Chief Medical Officer effective March 1, 2019. He will follow Dr Thor Voigt who will retire after 27 years of successful and dedicated service for the corporation at the end of April 2019.

Allan Hillgrove, Member of the Board of Managing Directors with responsibility for the Human Pharma Business Unit said: "In the pharmaceutical industry, the medical function is at the core of our success, which is based on the improvement we can provide to the health of patients. We are fortunate to have many strong leaders in this area, and thank Dr Voigt for his excellent contributions. He will have a great successor in Dr Shahidi who takes over this important role as Chief Medical Officer with a well-deserved, excellent reputation inside and outside our company.”

Dr. Mehdi Shahidi

Mehdi Shahidi joined Boehringer Ingelheim in 2005 as a clinical development lead for oncology. Over the following years, he assumed broader responsibilities in the Oncology TA in clinical development and medical affairs and in 2016 became Global Head of Medicine, Oncology. Dr Shahidi is a UK qualified Clinical Oncologist, obtained his medical degree in Tehran, and completed his specialist oncology training at the Royal Marsden Hospital, London. Prior to joining the pharmaceutical industry, he had a successful clinical and research career. A registered specialist in Pharmaceutical medicine, (Royal College of Physicians, UK), Dr Shahidi brings a wealth of insights working with patients and the broader healthcare community.

Boehringer Ingelheim

Improving the health and quality of life of patients is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention.

Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals. In 2017, Boehringer Ingelheim achieved net sales of nearly 18.1 billion euros. R&D expenditure, exceeding three billion euros, corresponded to 17.0 per cent of net sales.

As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment.

More information about Boehringer Ingelheim can be found on or in our annual report:

Record changed: 2019-06-09


Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81

More documents for Mehdi Shahidi

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px

» top